Skip to main content
. 2020 May 15;12(5):2281–2294.

Figure 2.

Figure 2

The clinical relevance of RNASEH2A in estrogen-receptor (ER)-positive breast cancer. A. RNASEH2A mRNA expression in normal breast tissues and breast adenocarcinoma tissues from the GSE3744 and GSE70947 datasets. B-E. Samples were grouped according to RNASEH2A mRNA expression levels; only data for the subgroup with the highest levels of RNASEH2A mRNA are presented. B and C. RNASEH2A mRNA levels associated with intrinsic molecular subtypes in the GSE25066 and TCGA datasets, respectively. D and E. Levels of RNASEH2A mRNA in subtypes determined by age, tumor size, Elson grade, presence of PR, HER2+ status, and TNM stages of breast cancer in pooled non-TCGA datasets and pooled TCGA datasets. PR; progesterone receptor; HER2+; human epidermal growth factor receptor 2-positive. Data represent the mean ± SE of the mean. **, P<0.01. *, P<0.05.